Logo

Zyomyx Pockets $27M in Series E Round

Jul 30, 2002

NEW YORK, July 30 - Zyomyx said today it has pocketed $27 million in a Series E round of private-equity financing.

Investors included existing group Credit Suisse First Boston Private Equity and newcomers Lilly BioVentures and GE Life Science and Technology Finance.

Zyomyx said the cash will go to help ramp up and launch its human cytokine protein-profiling biochip, due in early 2003.

Breaking News
The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.